Recent studies have demonstrated multiple interplays between melanoma oncogenic pathways, MUC1, the abovementioned tumoral immune checkpoints, MDSCs, and indoleamine 2,3-dioxygenase (IDO). The gene discussed is IDO2; the disease is melanoma.